Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Pacific Edge Advances US Recovery with Medicare Pricing Boost and Insurer Contracts
Pacific Edge secures new US insurer contracts as proposed Medicare rates rise up to 39%, advancing its bladder cancer testing recovery.
Latest Stories — SECTOR DESK
Austco Healthcare Expands Software Reach with $15m RTM Acquisition
Austco Healthcare is acquiring RTM for an estimated $15.26m, adding monitoring software used at 600+ Australian sites and expanding recurring revenue potential.
Medical Developments International Reports Stronger Penthrox Demand across Multiple Regions
Medical Developments International’s Penthrox volumes rose 37% in Europe and 24% in Australian hospitals, despite quarterly revenue falling $700,000 to $10.2m.
Clever Culture Systems Taps PSC Biotech to Expand APAS Independence Pharma Sales
Clever Culture Systems appoints PSC Biotech as sole sales agent for APAS Independence, targeting pharmaceutical makers in the US, Canada and Singapore.
PainChek Expands Sabra Health US Rollout To 23 Care Communities
PainChek expands Sabra US rollout to 23 care communities, securing 808 contracted memory care licences as it targets year-end activation.
Proteomics International Completes Independent Validation of PromarkerEndo to Diagnose Early-Stage Endometriosis
Proteomics International independently validates PromarkerEndo, showing 90% sensitivity for stage IV endometriosis, with commercial availability targeted for FY27.
EBR Systems Resets US Sales Strategy after WiSE Implant Slowdown
EBR Systems resets its US sales strategy after WiSE implants fell to 40 in the September quarter, as Medicare reimbursement rates rise by up to 93%.
Racura Oncology Advances to New RC220 Dose Level in Harness-1 Lung Cancer Trial
Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose.
Clarity Pharmaceuticals Hits SECuRE Cohort Expansion Main Group Recruitment Target
Clarity Pharmaceuticals hits SECuRE main-group recruitment target, advancing its prostate cancer therapy trial as Phase III planning gets underway.
Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
Cyclopharm’s Technegas unanimously recommended as China’s preferred ventilation agent for lung imaging by seven leading medical bodies.
Optiscan Imaging Moves Closer to Regulatory Clearance of Real-Time Surgical Imaging Platform
Optiscan Imaging submits InVue for FDA 510(k) review, moving its real-time surgical imaging platform closer to US clearance and commercialisation.
Dimerix Achieves First Patient Completion Milestone for DMX-200 Clinical Program
Dimerix’s DMX-200 program reaches a milestone as its first patient completes two years in the extension study, with 93% of eligible patients continuing.